You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
格隆匯港股聚焦(9.17)︱深高速獲招商公路舉牌;君實生物產品獲得FDA孤兒藥資格認定
格隆匯 09-17 23:11

【財務數據】

光匯石油(00933.HK)17/18財年中期盈轉虧至8500萬港元

中油港燃(08132.HK)19/20財年前三季度虧損收窄至2304.6萬港元

【業績預告】

中國高精密(00591.HK)預計年度虧損擴大至8600萬-9000萬元

新維國際控股(08086.HK)料年度除税後虧損大幅增加不少於70%

【運營數據】

北控清潔能源集團(01250.HK)前8月累計總髮電量同比增長約4.6%

訴訟處罰】

招商證券(06099.HK):仲裁庭裁決林某向招商資管償付融資本金4.09億元

首都信息(01075.HK):法院駁回廈門鋭泰隆的上訴

【股本重組】

金衞醫療(00801.HK)股份買賣單位改為每手80萬股

併購出售】

正商實業(00185.HK)斥6135.4萬元收購新鄉市一幅地塊

上實城市開發(00563.HK)附屬以4.29億元競得上海閔行區土地

中國鐵塔(00788.HK):中國國新擬掛牌轉讓出售達沃啟航不超50%股權

復星醫藥(02196.HK)擬450萬元收購易研雲(上海)醫療科技全部股權

【增發供股】

泰錦控股(08321.HK)擬折讓13.22%配售3200萬股 籌資330萬港元

重大事項

深圳高速公路股份(00548.HK)獲股東招商公路增持A股約217.72萬股及H股1965萬股

民信國際控股(08456.HK)股價異常波動 前控股股東陸秀娟悉數出售所持公司股權

ESR(01821.HK)股東擬配售股份

復星醫藥(02196.HK):深圳復星健康註冊資本增至約1.2億元

君實生物(01877.HK):產品“特瑞普利單抗”獲得FDA孤兒藥資格認定

石藥集團(01093.HK)注射用多西他賽(白蛋白結合型)獲美國臨牀試驗批件

紅星美凱龍(01528.HK)擬開展商業物業資產證券化業務

復星醫藥(02196.HK):天津星魅獲Raziel許可在中國獨家臨牀開發和商業化RZL012

復宏漢霖-B(02696.HK):HLX02與原研曲妥珠單抗在HER2陽性轉移性乳腺癌患者上的療效、安全性和藥代動力學相當

大唐新能源(01798.HK)實現裝機容量突破千萬千瓦

NEXION TECH(08420.HK)與XOX Bhd訂立臨時技術合夥協議

【回購註銷】

中國旺旺(00151.HK)9月17日耗資4817.05萬港元回購902.2萬股

中國燃氣(00384.HK)9月17日耗資2554.55萬港元回購121.84萬股

金鷹商貿集團(03308.HK)9月17日耗資310.48萬港元回購44萬股

雷蛇(01337.HK)9月17日耗資340萬港元回購200萬股

齊屹科技(01739.HK)9月17日耗資247.33萬港元回購113.3萬股

數碼通電訊(00315.HK)9月17日耗資206.9萬港元回購49.15萬股

富智康集團(02038.HK)9月17日耗資138.2萬港元回購140.2萬股

維信金科(02003.HK)9月17日耗資44萬港元回購10.6萬股

葉氏化工集團(00408.HK)9月17日耗資108.56萬港元回購42.8萬股

中國水務(00855.HK)9月17日耗資126萬港元回購20.6萬股

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account